Medtronic gets US FDA clearance for Riptide aspiration system

1786
Riptide aspiration system

The Riptide aspiration system is intended for use in the revascularisation of patients with acute ischaemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral—M1 and M2 segments, basilar and vertebral arteries) within eight hours of symptom onset.

The system is designed to retrieve thrombus through the Arc catheter and restore blood flow in patients experiencing ischaemic stroke. It adds a valuable tool to the acute ischaemic stroke product portfolio, a press release from the company states.

Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

“While I primarily use the Solitaire revascularisation device to treat patients with acute ischaemic stroke, I utilise a direct aspiration approach as my first line treatment strategy in select circumstances such as basilar artery thromboembolism and in select anterior circulation cases,” said Daniel Sahlein, interventional neuroradiologist, Goodman Campbell Brain and Spine, assistant professor of clinical neurology in the department of Neurological Surgery, Indianapolis University-Purdue University, Indianapolis, USA. “The Riptide Aspiration System will provide me with another proven Medtronic product to utilise when treating stroke patients.”

The Riptide aspiration system includes the Arc catheter, Riptide aspiration tubing, Riptide aspiration pump and Riptide collection canister with intermediate tubing. The Riptide aspiration system is a foundational platform for future aspiration catheters, currently in development.

“Medtronic is committed to developing services and solutions that address healthcare needs by improving clinical and economic outcomes,” said Stacey Pugh, vice president and general manager of Medtronic’s Neurovascular business which is part of the Restorative Therapies Group. “We believe that the Riptide aspiration system and Solitaire revascularisation device provide our customers with a comprehensive suite of products to choose from. Medtronic is committed to being a complete solutions provider in the treatment of acute ischaemic stroke market.”

 

(Visited 879 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here